An engineered extracellular vesicle and use thereof in the preparation of a product for treating an autoimmune disease
By overexpressing IDO1 or CSF1 in MSC-EVs, engineered extracellular vesicles MSC-IDO1-EVs or MSC-CSF1-EVs were prepared, solving the problem of poor therapeutic effects of MSC-EVs and achieving significant immunosuppression and inflammation relief effects.
CN122163650APending Publication Date: 2026-06-09SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
- Filing Date
- 2026-02-04
- Publication Date
- 2026-06-09
AI Technical Summary
Technical Problem
In existing technologies, MSC-EVs have insufficient levels of immune-regulating active factors when treating autoimmune diseases such as systemic lupus erythematosus, resulting in poor treatment efficacy.
Method used
Engineered extracellular vesicles MSC-IDO1-EVs or MSC-CSF1-EVs were prepared by overexpressing IDO1 or CSF1 in extracellular vesicles, thereby enhancing their immunosuppressive effects.
Benefits of technology
It significantly inhibits the proliferation of abnormal T/B cells, reduces the secretion of inflammatory cytokines, alleviates renal immune complex deposition and inflammation, and significantly improves the treatment effect of autoimmune diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122163650A_ABST
Abstract
This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art